三维适形放疗联合多西他赛周剂量同步化疗治疗中晚期食管鳞癌疗效观察

摘要

Objective To analyze the curative effect of three-dimensional conformal radiotherapy combined with concurrent chemotherapy of weekly dosage of docetaxel in the treatment of middle and advanced esophageal squamous cell carcinoma. MethodsClinical data of 72 patients with middle and advanced esophageal squamous cell carcinoma who were admitted to our hospital were selected and they are randomly allocated to the study group and the control group, with 36 in each. Patients in the study group were received three-dimensional conformal radiotherapy combined with concurrent chemotherapy of weekly dosage of docetaxel while patients in the control group were only received three-dimensional conformal radiotherapy. Clinical curative effects of patients in the two groups were compared. Results Clinical efficacy rate of the study group was 83.33% which was significantly higher than that of the control group 69.44% (P<0.05). Survival rates of the first, second and third year in the study group were 72.22%, 61.11% and 33.33% respectively which were significantly than those in the control group 47.22%, 41.67% and 27.78%. The difference was statistically significant(P<0.05). Myelosuppression increased in the study group when compared with the control group but the treatments in two groups were both completed after clinical management.Conclusion Three-dimensional conformal radiotherapy combined with concurrent chemotherapy of weekly dosage of docetaxel in the treatment of middle and advanced esophageal squamous cell carcinoma has a good curative effect and bearable toxic side effects and it can improve the short-term survival rate of patients. Whether it is beneficial to long-term survival still needs a follow-up observation which is worthy of clinical promotion.%目的：分析三维适形放疗联合多西他赛周剂量同步化疗治疗中晚期食管鳞癌的疗效。方法选取本院收治的72例中晚期食管鳞癌患者临床资料，随机分为研究组及对照组，各36例。研究组应用三维适形放疗联合多西他赛周剂量同步化疗治疗，对照组单纯应用三维适形放疗，对比患者临床疗效。结果研究组临床总有效率为83.33%，明显高于对照组的69.44%（P＜0.05）。研究组第1、2、3年生存率分别为72.22%、61.11%、33.33%，明显高于对照组的47.22%、41.67%、27.78%，差异有统计学意义（P＜0.05）。同步放化组骨髓抑制较单纯放疗组有所增加，但经临床处理后均顺利完成治疗过程。结论三维适形放疗联合多西他赛周剂量同步化疗治疗中晚期食管鳞癌，疗效较高，毒副反应能耐受，提高患者近期生存率，远期生存是否得益尚需继续随访观察，值得临床推广。